skip to content
home ver. 2.3. site index contact us
Schering-Plough
About Us Products and Care R&D Partnerships News and Media Investor Relations Corporate Responsibility Careers
Message from the CEO
How We Work
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

Management Biographies

THOMAS J. SABATINO JR.
Executive Vice President and General Counsel
Schering-Plough Corporation
Kenilworth, New Jersey

Thomas J. Sabatino Jr. is executive vice president and general counsel of Schering-Plough Corporation.

He is responsible for overseeing the legal operations of the company, including formulating corporate legal policy and supervising inside and outside counsel and directing corporate activities pertaining to corporate communications, federal legislation, government relations and corporate security.

Sabatino joined Schering-Plough in his present position on April 15, 2004. He most recently served as senior vice president and general counsel for Baxter International Inc. in Deerfield, Ill. Sabatino, who had two tenures at Baxter, first joined that company in 1986 as corporate counsel, working with Baxter's former Systems and Medical Specialty Device divisions and heading Baxter's legal team in the establishment of the IBAX joint venture in 1989. In 1990, he left Baxter to join Secure Medical, Inc., Mundelein, Ill., as president and chief executive officer. In 1992, he was named associate general counsel for American Medical International Inc., Dallas, Texas, becoming vice president and general counsel in 1993. American Medical International later merged with National Medical Enterprises to become Tenet Healthcare Corporation. In 1995, he left Tenet to rejoin Baxter as associate general counsel. He was named general counsel in 1997 and added the title senior vice president in 2001. Sabatino has also worked for law firms in both Chicago and Boston during his career.

Sabatino earned a B.A. degree, cum laude, from Wesleyan University and a J.D. degree from the University of Pennsylvania Law School.

He is a member of the Bar in California, Illinois and Massachusetts.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

 

Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
HomeAbout UsProducts & CareR&DPartnerships
News & MediaInvestor RelationsCorporate ResponsibilityCareers
Contact Us Site Index
© 2003 - 2008 Schering-Plough Corporation.
Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough